Kenya is set to launch a groundbreaking HIV-prevention drug called Lenacapavir in March, which can provide over 99.9 percent protection against HIV transmission with just two doses annually. The announcement comes as the country navigates changing foreign aid dynamics, particularly under the Trump administration, which has been marked by aid cuts to African nations. The Kenyan government received its first shipment of 21,000 doses, facilitated by a collaboration with the Global Fund, with a further 12,000 doses expected shortly after.

Health Minister Aden Duale indicated that the first phase of the rollout will target 15 counties, aiming to address the significant health challenge posed by HIV in the region. Eastern and southern Africa, where Kenya is located, is particularly affected, with over half of the 40.8 million people living with HIV globally residing in these areas. This strategic move is crucial for Kenya, which has a 3.7 percent HIV prevalence rate, as it aims to improve health outcomes and align with international health initiatives.

In light of uncertainty regarding U.S. foreign aid, which is pivotal for many African health programs, the introduction of Lenacapavir represents an innovative approach to HIV prevention that Kenya hopes will bolster its health system. The country has also secured an additional 25,000 doses from U.S. commitments, underscoring a collaborative approach to healthcare funding and delivery in the face of potential resource scarcity. This new drug and the associated rollout plan highlight Kenya's proactive steps towards combating the HIV epidemic while managing external funding challenges.